Illimis Therapeutics is a Seoul-based biotechnology company developing protein-based medicines for central nervous system and immune diseases. Its proprietary GAIA (Gas6-mediated Anti-Inflammatory Adaptor) platform builds bispecific fusion proteins that engage the body's TAM receptors to clear misfolded proteins such as amyloid-beta through phagocytosis without triggering the inflammation and ARIA side effects associated with existing antibody drugs. Founded in 2021, the company raised a $42 million Series B in July 2025 and is advancing a lead Alzheimer's candidate, ILM01, toward an IND by the end of 2027.
Samsung Electronics is a South Korean multinational and the flagship of the Samsung Group, one of the world's largest technology companies. It designs and manufactures smartphones, TVs, home appliances, displays, and memory and logic semiconductors. Best known for its Galaxy mobile line, Samsung is also the world's largest memory-chip maker and a central supplier of components to the wider electronics industry - including rivals. The company operates around the mission 'Inspire the World, Create the Future.'
ATAD Corp. is a Seoul-based technology company building an AI-driven multi-cloud operating platform that helps teams run AWS, Azure, and GCP environments from one place. Its flagship product, ODiiN, uses AI to forecast and self-heal infrastructure problems, claiming up to 80% cost savings and large productivity gains. Founded in 2023 by cloud and cybersecurity specialists, ATAD pairs cloud automation with a security stack built on AI, multi-factor authentication, and zero-knowledge proofs, and also runs Heiimdahl (a multi-LLM monitoring gateway) and Kraton (a blockchain-based decentralized VPN). The company has raised about $3.36M and holds a growing portfolio of patents in multi-cloud integration and secure data distribution.
Avelos Therapeutics is a Seoul-based clinical-stage oncology biotech founded in 2021 that designs small-molecule drugs for 'undruggable' cancer targets using synthetic lethality, DNA damage response (DDR), and cell-cycle biology. Its lead program, AD1208, is a first-in-class oral MASTL kinase inhibitor now in a Phase 1/2a solid-tumor trial. Backed by KRW 30 billion (~$21.7M) across seed, Series A, and a 2024 Series B, the roughly nine-person team is building a biomarker-driven pipeline of four anti-cancer candidates aimed at a future KOSDAQ listing.